Ake­bia touts da­ta for two PhI­II stud­ies, set­ting up show­down with As­traZeneca, Fi­bro­Gen

Three months af­ter their com­mer­cial part­ner Vi­for dropped $100 mil­lion on a pri­or­i­ty re­view vouch­er for their ex­per­i­men­tal ane­mia drug, Ake­bia tout­ed the re­sults …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER